Which Generation TKI Is Repotrectinib? Professional Analysis of Next-Gen ROS1 Inhibitor Classification and Clinical Features

　　Repotrectinib is a novel multi-target tyrosine kinase inhibitor primarily acting on ROS1,NTRK,and ALK targets,used for treating ROS1 fusion-positive non-small cell lung cancer(NSCLC)and NTRK fusion-positive solid tumors.Understanding its generational classification requires professional analysis of ROS1 and NTRK targeted therapy development history.

　　1.Generational Evolution of ROS1 Inhibitors

　　In the ROS1 targeted therapy field,drug generation classification is primarily based on development timeline,target coverage,and resistance mutation management capabilities.The first-generation representative drug is Crizotinib,the first ROS1/ALK/MET inhibitor with clear efficacy but poor brain metastasis control and prone to resistance.The second-generation representative drug is Entrectinib,a ROS1/NTRK/ALK inhibitor with improved brain metastasis efficacy and safety.Repotrectinib is referred to by the industry as next-generation or third-generation ROS1/NTRK inhibitor,with molecular design specifically targeting common ROS1 G2032R mutations after Crizotinib and Entrectinib resistance,offering stronger activity and broader resistance coverage.

　　2.Core Advantages of Repotrectinib

　　As a next-generation ROS1/NTRK inhibitor,Repotrectinib has the following outstanding features.First is optimized structure with small molecular weight and high activity,effective against ROS1 G2032R,L2026M and other resistance mutations.Second is strong CNS penetration with excellent blood-brain barrier penetration and significant control effect on brain metastases.Third is broad indications,also effective against NTRK fusion-positive tumors;this indication was approved in China in January 2026.Fourth is manageable safety with adverse reaction profile similar to comparable drugs and overall acceptable safety.

　　3.Clinical Treatment Sequence Positioning

　　Repotrectinib has flexible positioning in treatment sequence.For first-line treatment,newly diagnosed ROS1 fusion-positive NSCLC patients can use Repotrectinib as a first-line choice,with advantages in resistance mutation coverage and intracranial efficacy.For later-line salvage treatment,patients progressing after Crizotinib or Entrectinib treatment,if ROS1 resistance mutations(such as G2032R)are detected,Repotrectinib is an important later-line treatment option.Repotrectinib was approved in China in May 2024,included in the National Reimbursement Drug List in November 2024,and officially implemented from January 1,2025,significantly reducing patient medication costs.

　　4.Distinction from ALK Inhibitor Generations

　　It should be noted that while Repotrectinib also inhibits ALK,its primary positioning is as a ROS1/NTRK inhibitor.Data in ALK-positive NSCLC is relatively limited,so it is not used as a standard reference for ALK inhibitor generation classification.In ALK inhibitor generation classification,Crizotinib is first generation,Alectinib etc.are second generation,and Lorlatinib is third generation.

　　5.Summary

　　As a next-generation ROS1/NTRK targeted drug,Repotrectinib has significant advantages in resistance mutation management,brain metastasis control,and indication coverage.Whether for first-line treatment of newly diagnosed patients or salvage treatment after resistance,Repotrectinib provides an important treatment option for ROS1 and NTRK fusion-positive tumor patients.